Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Linlin Guo, Jay Overholser, Heather Darby, Nicholas J. Ede & Pravin T.P Kaumaya. (2022) A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx). OncoImmunology 11:1.
Read now
Read now
Wei Xia, Liping He, Jingxiao Bao, Yifei Qi & John Z.H. Zhang. (2022) Insights into small molecule inhibitor bindings to PD-L1 with residue-specific binding free energy calculation. Journal of Biomolecular Structure and Dynamics 40:22, pages 12277-12285.
Read now
Read now
Jingjing Deng, Zhengqi Cheng, Juyang Long, Alexander Dömling, Micky Tortorella & Yuanze Wang. (2022) Small Molecule Inhibitors of Programmed Cell Death Ligand 1 (PD-L1): A Patent Review (2019–2021). Expert Opinion on Therapeutic Patents 32:5, pages 575-589.
Read now
Read now
Jorge Cebada, Martin Perez-Santos, Cindy Bandala, Eleazar Lara-Padilla, Irma Herrera-Camacho, Nora Hilda Rosas-Murrieta, Lourdes Millán-Pérez Peña, Eduardo Monjaraz, Amira Flores & Maricruz Anaya-Ruiz. (2021) OX40 agonists for cancer treatment: a patent review. Expert Opinion on Therapeutic Patents 31:1, pages 81-90.
Read now
Read now
Leilei Ai, Jian Chen, Hao Yan, Qiaojun He, Peihua Luo, Zhifei Xu & Xiaochun Yang. (2020) Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. Drug Design, Development and Therapy 14, pages 3625-3649.
Read now
Read now
Qiaohong Geng, Sagar O. Rohondia, Harras J. Khan, Peifu Jiao & Q. Ping Dou. (2020) Small molecules as antagonists of co-inhibitory pathways for cancer immunotherapy: a patent review (2018-2019). Expert Opinion on Therapeutic Patents 30:9, pages 677-694.
Read now
Read now
Martin Perez-Santos, Maricruz Anaya-Ruiz, Jorge Cebada, Cindy Bandala, Gerardo Landeta, Patricia Martínez-Morales & Nemesio Villa-Ruano. (2019) LAG-3 antagonists by cancer treatment: a patent review. Expert Opinion on Therapeutic Patents 29:8, pages 643-651.
Read now
Read now
Articles from other publishers (44)
Mohammad Kaisarul Islam & Johnson Stanslas. (2021) Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer. Pharmacology & Therapeutics 227, pages 107870.
Crossref
Crossref
Hao Cao, Binbin Cheng, Ting Liu & Jianjun Chen. (2021) Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment. Biochemical Pharmacology 188, pages 114522.
Crossref
Crossref
Roberto Butera, Marta Ważyńska, Katarzyna Magiera-Mularz, Jacek Plewka, Bogdan Musielak, Ewa Surmiak, Dominik Sala, Radoslaw Kitel, Marco de Bruyn, Hans W. Nijman, Philip H. Elsinga, Tad A. Holak & Alexander Dömling. (2021) Design, Synthesis, and Biological Evaluation of Imidazopyridines as PD-1/PD-L1 Antagonists. ACS Medicinal Chemistry Letters 12:5, pages 768-773.
Crossref
Crossref
Donald J. AbrahamAndrew W. Buesking, Patrick A. Mayes & Andrew P. Combs. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
30
.
Chang Liu, Navindra P. Seeram & Hang Ma. (2021) Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review. Cancer Cell International 21:1.
Crossref
Crossref
Yuchen Wang, Xiao Liu, Xiaowen Zou, Shuting Wang, Lijun Luo, Yuke Liu, Kai Dong, Xiaoqing Yao, Yan Li, Xiaoguang Chen & Li Sheng. (2021) Metabolism and Interspecies Variation of IMMH-010, a Programmed Cell Death Ligand 1 Inhibitor Prodrug. Pharmaceutics 13:5, pages 598.
Crossref
Crossref
Khalaf Kridin, Jennifer E. Hundt, Ralf J. Ludwig, Kyle T. Amber, Dana Tzur Bitan & Arnon D. Cohen. (2021) Melanoma is associated with an increased risk of bullous pemphigoid: a large population-based longitudinal study. Archives of Dermatological Research.
Crossref
Crossref
Fengling Wang, Wenling Ye, Shuang Wang, Yongxing He, Haiyang Zhong, Yuwei Wang, Yongchang Zhu, Jianting Han, Zhitong Bing, Shaoping Ji, Huanxiang Liu & Xiaojun Yao. (2021) Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy. Neoplasia 23:3, pages 281-293.
Crossref
Crossref
Chenghao Pan, Haiyan Yang, Yang Lu, Shengquan Hu, Yizhe Wu, Qiaojun He & Xiaowu Dong. (2021) Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation. European Journal of Medicinal Chemistry 213, pages 113170.
Crossref
Crossref
Xuchao Yang, Binbin Cheng, Yao Xiao, Mingming Xue, Ting Liu, Hao Cao & Jianjun Chen. (2021) Discovery of novel CA-4 analogs as dual inhibitors of tubulin polymerization and PD-1/PD-L1 interaction for cancer treatment. European Journal of Medicinal Chemistry 213, pages 113058.
Crossref
Crossref
Zhiru Wang, Wenting Kang, Ouwen Li, Fengyu Qi, Junwei Wang, Yinghua You, Pengxing He, Zhenhe Suo, Yichao Zheng & Hong-Min Liu. (2021) Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. Acta Pharmaceutica Sinica B 11:3, pages 694-707.
Crossref
Crossref
Mohammad Taghi Nazeri, Ali Beygzade Nowee & Ahmad Shaabani. (2021)
A new one-pot synthesis of pseudopeptide connected to sulfonamide
via
the tandem
N
-sulfonylation/Ugi reactions
. New Journal of Chemistry 45:7, pages 3479-3484.
Crossref
Crossref
Yang Yang, Ke Wang, Hao Chen & Zhiqiang Feng. (2021) Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction. European Journal of Medicinal Chemistry 211, pages 113001.
Crossref
Crossref
Katarzyna Magiera-Mularz, Justyna Kocik, Bogdan Musielak, Jacek Plewka, Dominik Sala, Monika Machula, Przemyslaw Grudnik, Malgorzata Hajduk, Marcin Czepiel, Maciej Siedlar, Tad A. Holak & Lukasz Skalniak. (2021) Human and mouse PD-L1: similar molecular structure, but different druggability profiles. iScience 24:1, pages 101960.
Crossref
Crossref
Fazhi Yu, Chenyu Zhu, Qiong Xie & Yonghui Wang. (2020)
Adenosine A
2A
Receptor Antagonists for Cancer Immunotherapy
. Journal of Medicinal Chemistry 63:21, pages 12196-12212.
Crossref
Crossref
Jang-Gi Choi, Young Soo Kim, Ji Hye Kim, Tae In Kim, Wei Li, Tae Woo Oh, Chang Hyun Jeon, Su Jin Kim & Hwan-Suck Chung. (2020) Anticancer Effect of Salvia plebeia and Its Active Compound by Improving T-Cell Activity via Blockade of PD-1/PD-L1 Interaction in Humanized PD-1 Mouse Model. Frontiers in Immunology 11.
Crossref
Crossref
Magdalena Konieczny, Bogdan Musielak, Justyna Kocik, Lukasz Skalniak, Dominik Sala, Miroslawa Czub, Katarzyna Magiera-Mularz, Ismael Rodriguez, Maja Myrcha, Malgorzata Stec, Maciej Siedlar, Tad A. Holak & Jacek Plewka. (2020) Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint. Journal of Medicinal Chemistry 63:19, pages 11271-11285.
Crossref
Crossref
Christian Bailly & Gérard Vergoten. (2020) N-glycosylation and ubiquitinylation of PD-L1 do not restrict interaction with BMS-202: A molecular modeling study. Computational Biology and Chemistry 88, pages 107362.
Crossref
Crossref
Christian Bailly & Gérard Vergoten. (2020) Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer. Biochemical Pharmacology 178, pages 114042.
Crossref
Crossref
Simon Van Herck & Bruno G. De Geest. (2020) Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics. Acta Pharmacologica Sinica 41:7, pages 881-894.
Crossref
Crossref
Christian Bailly & Gérard Vergoten. (2020) Protein homodimer sequestration with small molecules: Focus on PD-L1. Biochemical Pharmacology 174, pages 113821.
Crossref
Crossref
Marta Spodzieja, Katarzyna Kuncewicz, Adam Sieradzan, Agnieszka Karczyńska, Justyna Iwaszkiewicz, Valérie Cesson, Katarzyna Węgrzyn, Igor Zhukov, Martyna Maszota-Zieleniak, Olivier Michielin, Daniel E. Speiser, Vincent Zoete, Laurent Derré & Sylwia Rodziewicz-Motowidło. (2020) Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding. International Journal of Molecular Sciences 21:2, pages 636.
Crossref
Crossref
Xin Lin, Xiang Lu, Guoshun Luo & Hua Xiang. (2020) Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules. European Journal of Medicinal Chemistry 186, pages 111876.
Crossref
Crossref
Mingze Qin, Qi Cao, Xia Wu, Chunyang Liu, Shuaishuai Zheng, Hongbo Xie, Ye Tian, Jun Xie, Yanfang Zhao, Yunlei Hou, Xian Zhang, Boxuan Xu, Haotian Zhang & Xiaobo Wang. (2020) Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold. European Journal of Medicinal Chemistry 186, pages 111856.
Crossref
Crossref
Jindřich Kopeček & Jiyuan Yang. (2020) Polymer nanomedicines. Advanced Drug Delivery Reviews 156, pages 40-64.
Crossref
Crossref
Yunsheng Yuan. 2020. Regulation of Cancer Immune Checkpoints. Regulation of Cancer Immune Checkpoints
531
546
.
Wenfei Chen, Zhaofei Guo, Yining Zhu, Nan Qiao, Zhirong Zhang & Xun Sun. (2019) Combination of Bacterial‐Photothermal Therapy with an Anti‐PD‐1 Peptide Depot for Enhanced Immunity against Advanced Cancer. Advanced Functional Materials 30:1, pages 1906623.
Crossref
Crossref
Tadashi ASHIZAWA, Akira IIZUKA, Emiko TANAKA, Ryota KONDOU, Haruo MIYATA, Chie MAEDA, Takashi SUGINO, Ken YAMAGUCHI, Takayuki ANDO, Yoshinobu ISHIKAWA, Mamoru ITO & Yasuto AKIYAMA. (2019) Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. Biomedical Research 40:6, pages 243-250.
Crossref
Crossref
Yunxia Wang, Song Zhang, Fengcheng Li, Ying Zhou, Ying Zhang, Zhengwen Wang, Runyuan Zhang, Jiang Zhu, Yuxiang Ren, Ying Tan, Chu Qin, Yinghong Li, Xiaoxu Li, Yuzong Chen & Feng Zhu. (2019) Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Research.
Crossref
Crossref
Cyril Leven, Maël Padelli, Jean-Luc Carré, Eric Bellissant & Laurent Misery. (2019) Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure–Response Relationships. Clinical Pharmacokinetics 58:11, pages 1393-1405.
Crossref
Crossref
Rita C. Acúrcio, Carlota Leonardo-Sousa, Alfonso T. García-Sosa, Jorge A. Salvador, Helena F. Florindo & Rita C. Guedes. (2019) Structural insights and binding analysis for determining the molecular bases for programmed cell death protein ligand-1 inhibition. MedChemComm 10:10, pages 1810-1818.
Crossref
Crossref
Claudia Mejías & Osmany Guirola. (2019) Pharmacophore model of immunocheckpoint protein PD-L1 by cosolvent molecular dynamics simulations. Journal of Molecular Graphics and Modelling 91, pages 105-111.
Crossref
Crossref
Yue Li, Grishma Acharya, Mina Elahy, Hong Xin & Levon M. Khachigian. (2019) The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation. Cancer Letters 459, pages 268-276.
Crossref
Crossref
Aravindhan Ganesan, Marawan Ahmed, Isobel Okoye, Elena Arutyunova, Dinesh Babu, William L. Turnbull, Joydeb Kumar Kundu, Justin Shields, Katharine Cheryl Agopsowicz, Lai Xu, Yasser Tabana, Nutan Srivastava, Guangzhi Zhang, Tae Chul Moon, Alexandr Belovodskiy, Mostofa Hena, Appan Srinivas Kandadai, Seyedeh Nargess Hosseini, Mary Hitt, John Walker, Michael Smylie, Frederick G. West, Arno G. Siraki, M. Joanne Lemieux, Shokrollah Elahi, James A. Nieman, D. Lorne Tyrrell, Michael Houghton & Khaled Barakat. (2019) Comprehensive in vitro characterization of PD-L1 small molecule inhibitors. Scientific Reports 9:1.
Crossref
Crossref
Knut Biber, Anindya Bhattacharya, Brian M. Campbell, Justin R. Piro, Michael Rohe, Roland G.W. Staal, Robert V. Talanian & Thomas Möller. (2019) Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development. Frontiers in Pharmacology 10.
Crossref
Crossref
Subhadwip Basu, Jeffrey Yang, Bin Xu, Katarzyna Magiera-Mularz, Lukasz Skalniak, Bogdan Musielak, Vladyslav Kholodovych, Tad A. Holak & Longqin Hu. (2019)
Design, Synthesis, Evaluation, and Structural Studies of
C
2
-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
. Journal of Medicinal Chemistry 62:15, pages 7250-7263.
Crossref
Crossref
Bogdan Musielak, Justyna Kocik, Lukasz Skalniak, Katarzyna Magiera-Mularz, Dominik Sala, Miroslawa Czub, Malgorzata Stec, Maciej Siedlar, Tad A. Holak & Jacek Plewka. (2019) CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?. Molecules 24:15, pages 2804.
Crossref
Crossref
Qian Yang, Jinrong Peng, Kun Shi, Yao Xiao, Qingya Liu, Ruxia Han, Xiawei Wei & Zhiyong Qian. (2019) Rationally designed peptide-conjugated gold/platinum nanosystem with active tumor-targeting for enhancing tumor photothermal-immunotherapy. Journal of Controlled Release 308, pages 29-43.
Crossref
Crossref
Katarzyna Guzik, Marcin Tomala, Damian Muszak, Magdalena Konieczny, Aleksandra Hec, Urszula Błaszkiewicz, Marcin Pustuła, Roberto Butera, Alexander Dömling & Tad A. Holak. (2019) Development of the Inhibitors That Target the PD-1/PD-L1 Interaction—A Brief Look at Progress on Small Molecules, Peptides and Macrocycles. Molecules 24:11, pages 2071.
Crossref
Crossref
Mingze Qin, Qi Cao, Shuaishuai Zheng, Ye Tian, Haotian Zhang, Jun Xie, Hongbo Xie, Yajing Liu, Yanfang Zhao & Ping Gong. (2019)
Discovery of [1,2,4]Triazolo[4,3-
a
]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction
. Journal of Medicinal Chemistry 62:9, pages 4703-4715.
Crossref
Crossref
Kanin Wichapong, Hessel Poelman, Bogac Ercig, Johana Hrdinova, Xiaosong Liu, Esther Lutgens & Gerry AF Nicolaes. (2019) Rational modulator design by exploitation of protein–protein complex structures. Future Medicinal Chemistry 11:9, pages 1015-1033.
Crossref
Crossref
Janna Krueger, Christopher E. Rudd & Alison Taylor. (2019) Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications. Seminars in Immunology 42, pages 101295.
Crossref
Crossref
Abdul Abbas, Bingjing Lin, Chen Liu, Arwa Morshed, Jialiang Hu & Hanmei Xu. (2019) Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor Activity. International Journal of Molecular Sciences 20:3, pages 572.
Crossref
Crossref
Gan Wang, Le Wang, Jianlong Zhou & Xiaoxin Xu. (2019)
The Possible Role of PD-1 Protein in
Ganoderma lucidum
–Mediated Immunomodulation and Cancer Treatment
. Integrative Cancer Therapies 18, pages 153473541988027.
Crossref
Crossref